TipRanks
CSPC Pharmaceutical Group Limited (MX:1093N)
:1093N
Mexico Market

CSPC Pharmaceutical Group (1093N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1093N Analyst Ratings

Strong Buy
14Ratings
Strong Buy
13 Buy
0 Hold
1 Sell
Based on 14 analysts giving stock ratings to
CSPC
Pharmaceutical Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1093N Stock 12 Month Forecast

Average Price Target

$28.97
▲(81.05% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for CSPC Pharmaceutical Group in the last 3 months. The average price target is $28.97 with a high forecast of $42.61 and a low forecast of $17.61. The average price target represents a 81.05% change from the last price of $16.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","43":"$43","21.25":"$21.3","28.5":"$28.5","35.75":"$35.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42.6089158,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.968214708035713,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.60699,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,21.25,28.5,35.75,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16,18.046839676923078,20.093679353846156,22.14051903076923,24.187358707692308,26.234198384615386,28.28103806153846,30.327877738461538,32.374717415384616,34.421557092307694,36.46839676923077,38.51523644615385,40.56207612307692,{"y":42.6089158,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16,16.99755497754121,17.995109955082416,18.992664932623626,19.990219910164836,20.987774887706045,21.98532986524725,22.98288484278846,23.98043982032967,24.977994797870878,25.975549775412087,26.973104752953297,27.970659730494503,{"y":28.968214708035713,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16,16.123614615384614,16.247229230769232,16.370843846153846,16.49445846153846,16.61807307692308,16.741687692307693,16.865302307692307,16.98891692307692,17.11253153846154,17.236146153846153,17.359760769230768,17.483375384615385,{"y":17.60699,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.49,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.662,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.662,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.662,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.662,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.662,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.662,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.662,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.662,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$42.61Average Price Target$28.97Lowest Price Target$17.61
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
DBS
$30.15
Buy
88.45%
Upside
Initiated
09/10/26
Analysts' Top Healthcare Picks: Viking Therapeutics (VKTX), CSPC Pharmaceutical Group (CHJTF)
UBS Analyst forecast on MX:1093N
Unknown Analyst
UBS
Not Ranked
UBS
$23.99$25.97
Buy
62.31%
Upside
Reiterated
08/27/26
CSPC Pharmaceutical Group (CHJTF) Gets a Buy from UBS
Citic Securities Analyst forecast on MX:1093N
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
$39.62
Buy
147.60%
Upside
Reiterated
08/25/26
Citic Securities Keeps Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
Jefferies Analyst forecast on MX:1093N
Jefferies
Jefferies
$17.61
Sell
10.04%
Upside
Reiterated
08/24/26
Analysts Conflicted on These Healthcare Names: Natera (NASDAQ: NTRA), Healthequity (NASDAQ: HQY) and CSPC Pharmaceutical Group (Other OTC: CHJTF)
CICC Analyst forecast on MX:1093N
Unknown Analyst
CICC
Not Ranked
CICC
$26.41
Buy
65.07%
Upside
Reiterated
08/22/26
CICC Keeps Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
CLSA Analyst forecast on MX:1093N
Unknown Analyst
CLSA
Not Ranked
CLSA
$41.82
Buy
161.35%
Upside
Reiterated
08/21/26
CLSA Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF)
CMB International Securities Analyst forecast on MX:1093N
CMB International Securities
CMB International Securities
$28.72$29.58
Buy
84.87%
Upside
Reiterated
08/21/26
CSPC Pharmaceutical: Buy Rating Reaffirmed as Earnings Visibility Improves and DCF-Based Target Price Raised to HK$13.44
Citi
$25.31$30.81
Buy
92.58%
Upside
Reiterated
08/21/26
CSPC Pharmaceutical Group (CHJTF) Receives a Buy from Citi
Huatai Securities Analyst forecast on MX:1093N
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
$42.61
Buy
166.31%
Upside
Reiterated
08/21/26
CSPC Pharmaceutical Group (CHJTF) Receives a Buy from Huatai Securities
Morgan Stanley Analyst forecast on MX:1093N
Morgan Stanley
Morgan Stanley
$24.21
Buy
51.31%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (NASDAQ: MRKR) and CSPC Pharmaceutical Group (Other OTC: CHJTF)
Guosheng Securities Analyst forecast on MX:1093N
Unknown Analyst
Guosheng Securities
Not Ranked
Guosheng Securities
$29.51
Buy
84.46%
Upside
Reiterated
08/19/26
Guosheng Securities Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
Daiwa Analyst forecast on MX:1093N
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$24.21
Buy
51.31%
Upside
Reiterated
08/12/26
Daiwa Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
Nomura Analyst forecast on MX:1093N
Unknown Analyst
Nomura
Not Ranked
Nomura
$22.69
Buy
41.82%
Upside
Reiterated
07/24/26
Nomura Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF)
HSBC Analyst forecast on MX:1093N
Unknown Analyst
HSBC
Not Ranked
HSBC
$20.36
Buy
27.24%
Upside
Reiterated
07/10/26
HSBC Keeps Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
BOCOM International Holdings Company Analyst forecast on MX:1093N
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$17.72
Hold
10.73%
Upside
Reiterated
06/02/26
CSPC Pharmaceutical Group (CHJTF) Receives a Hold from BOCOM International Holdings Company
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
DBS
$30.15
Buy
88.45%
Upside
Initiated
09/10/26
Analysts' Top Healthcare Picks: Viking Therapeutics (VKTX), CSPC Pharmaceutical Group (CHJTF)
UBS Analyst forecast on MX:1093N
Unknown Analyst
UBS
Not Ranked
UBS
$23.99$25.97
Buy
62.31%
Upside
Reiterated
08/27/26
CSPC Pharmaceutical Group (CHJTF) Gets a Buy from UBS
Citic Securities Analyst forecast on MX:1093N
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
$39.62
Buy
147.60%
Upside
Reiterated
08/25/26
Citic Securities Keeps Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
Jefferies Analyst forecast on MX:1093N
Jefferies
Jefferies
$17.61
Sell
10.04%
Upside
Reiterated
08/24/26
Analysts Conflicted on These Healthcare Names: Natera (NASDAQ: NTRA), Healthequity (NASDAQ: HQY) and CSPC Pharmaceutical Group (Other OTC: CHJTF)
CICC Analyst forecast on MX:1093N
Unknown Analyst
CICC
Not Ranked
CICC
$26.41
Buy
65.07%
Upside
Reiterated
08/22/26
CICC Keeps Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
CLSA Analyst forecast on MX:1093N
Unknown Analyst
CLSA
Not Ranked
CLSA
$41.82
Buy
161.35%
Upside
Reiterated
08/21/26
CLSA Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF)
CMB International Securities Analyst forecast on MX:1093N
CMB International Securities
CMB International Securities
$28.72$29.58
Buy
84.87%
Upside
Reiterated
08/21/26
CSPC Pharmaceutical: Buy Rating Reaffirmed as Earnings Visibility Improves and DCF-Based Target Price Raised to HK$13.44
Citi
$25.31$30.81
Buy
92.58%
Upside
Reiterated
08/21/26
CSPC Pharmaceutical Group (CHJTF) Receives a Buy from Citi
Huatai Securities Analyst forecast on MX:1093N
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
$42.61
Buy
166.31%
Upside
Reiterated
08/21/26
CSPC Pharmaceutical Group (CHJTF) Receives a Buy from Huatai Securities
Morgan Stanley Analyst forecast on MX:1093N
Morgan Stanley
Morgan Stanley
$24.21
Buy
51.31%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (NASDAQ: MRKR) and CSPC Pharmaceutical Group (Other OTC: CHJTF)
Guosheng Securities Analyst forecast on MX:1093N
Unknown Analyst
Guosheng Securities
Not Ranked
Guosheng Securities
$29.51
Buy
84.46%
Upside
Reiterated
08/19/26
Guosheng Securities Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
Daiwa Analyst forecast on MX:1093N
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$24.21
Buy
51.31%
Upside
Reiterated
08/12/26
Daiwa Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
Nomura Analyst forecast on MX:1093N
Unknown Analyst
Nomura
Not Ranked
Nomura
$22.69
Buy
41.82%
Upside
Reiterated
07/24/26
Nomura Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF)
HSBC Analyst forecast on MX:1093N
Unknown Analyst
HSBC
Not Ranked
HSBC
$20.36
Buy
27.24%
Upside
Reiterated
07/10/26
HSBC Keeps Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
BOCOM International Holdings Company Analyst forecast on MX:1093N
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$17.72
Hold
10.73%
Upside
Reiterated
06/02/26
CSPC Pharmaceutical Group (CHJTF) Receives a Hold from BOCOM International Holdings Company
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
ASNDAscendis Pharma
HROWHarrow Health
IRTCIrhythm Technologies
DNLIDenali Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CSPC Pharmaceutical Group

3 Months
Jill WuCMB International Securities
Success Rate
10/16 ratings generated profit
63%
Average Return
+10.89%
Copying Jill Wu's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +10.89% per trade.
1 Year
Jill WuCMB International Securities
Success Rate
11/16 ratings generated profit
69%
Average Return
+25.03%
Copying Jill Wu's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +25.03% per trade.
2 Years
Jill WuCMB International Securities
Success Rate
14/16 ratings generated profit
88%
Average Return
+40.87%
Copying Jill Wu's trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +40.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1093N Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
9
8
8
7
7
Buy
4
3
7
9
8
Hold
3
1
1
1
0
Sell
4
2
2
1
1
Strong Sell
0
0
0
0
0
total
20
14
18
18
16
In the current month, 1093N has received 15 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. 1093N average Analyst price target in the past 3 months is 28.97.
Each month's total comprises the sum of three months' worth of ratings.

1093N Financial Forecast

1093N Earnings Forecast

Next quarter’s earnings estimate for 1093N is $0.20 with a range of $0.05 to $0.36. The previous quarter’s EPS was $1.18. 1093N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1093N has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1093N is $0.20 with a range of $0.05 to $0.36. The previous quarter’s EPS was $1.18. 1093N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1093N has Performed in-line its overall industry.

1093N Sales Forecast

Next quarter’s sales forecast for 1093N is $16.79B with a range of $15.91B to $17.67B. The previous quarter’s sales results were $46.36B. 1093N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1093N has Performed in-line its overall industry.
Next quarter’s sales forecast for 1093N is $16.79B with a range of $15.91B to $17.67B. The previous quarter’s sales results were $46.36B. 1093N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1093N has Performed in-line its overall industry.

1093N Stock Forecast FAQ

What is MX:1093N’s average 12-month price target, according to analysts?
Based on analyst ratings, CSPC Pharmaceutical Group Limited’s 12-month average price target is 28.97.
    What is MX:1093N’s upside potential, based on the analysts’ average price target?
    CSPC Pharmaceutical Group Limited has 81.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CSPC Pharmaceutical Group Limited a Buy, Sell or Hold?
          CSPC Pharmaceutical Group Limited has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 1 sell ratings.
            What is CSPC Pharmaceutical Group Limited’s share price target?
            The average share price target for CSPC Pharmaceutical Group Limited is 28.97. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $42.61 ,and the lowest forecast is $17.61. The average share price target represents 81.05% Increase from the current price of $16.
              What do analysts say about CSPC Pharmaceutical Group Limited?
              CSPC Pharmaceutical Group Limited’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of CSPC Pharmaceutical Group Limited?
                To buy shares of MX:1093N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.